Older publications (2012 - 2015)

2015

MM a MGUS

  1. Bacovsky J, Myslivecek M, Minarik J, Scudla V, Pika T, Zapletalova J, Petrova P, Bartkova M, Adam T, Gronowitz SJ. Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance-comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):135-8. doi: 10.5507/bp.2014.008. IF 1,661
  2. Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Slaby O, Kuglik P, Almasi M, Penka M, Krejci M, Adam Z, Pour L, Sevcikova S, Hajek R. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma. PLoS One. 2015;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015. IF 3,534
  3. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. J Mol Diagn. 2015;17(6):652-60. pii: S1525-1578(15)00147-6. doi: 10.1016/j.jmoldx.2015.05.007. IF 3,955
  4. Hrabálek L, Wanek T, Bačovský J, Minařík J, Ščudla V. Algoritmus operací mnohočetného myelomu a solitárního plazmocytomu páteře. Česká a Slovenská neurologie a neurochirurgie. 2015;78/111(1): 64-71. IF 0,159
  5. Jelinek T, Vsianska P, Hajek R. Monoklonální protilátky v léčbě mnohočetného myelomu, Transfuze Hematol. Dnes 21, 2015, No. 2, p. 74-83
  6. Jelinek T, Kryukov F, Rihova L, Hajek R. Plasma cell leukemia: from biology to treatment. Eur J Haematol. 2015 Jul;95(1):16-26 IF 2,414
  7. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-31. doi: 10.1056/NEJMoa1505654. IF 54,42
  8. Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, Autzinger EM, Heintel D, Greil R, Poenisch W, Müldür E, Zojer N. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica. 2015;100(3):385-91, pii: haematol.2014.115204. IF 5,868
  9. Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015;171(3):344-54. doi: 10.1111/bjh.13582. IF 4,959
  10. Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One. 2015;10(4):e0123866. doi: 10.1371/journal.pone.0123866. eCollection 2015. IF 3,534
  11. Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S, Spicka I, Chanan-Khan AA, Raab MS, Tarantolo S, Vij R, Zonder JA, Huang X, Jayabalan D, Di Liberto M, Huang X, Jiang Y, Kim ST, Randolph S, Chen-Kiang S. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015;56(12):3320-8.IF 2,605
  12. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Spička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma. Am J Hematol. 2015;90(1):42-9. doi: 10.1002/ajh.23868. IF 3,477
  13. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood. 2015;125(13):2068-74 pii: blood-2014-12-615187.  IF 9,775
  14. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2015;33(30):3459-66. pii: JCO.2014.60.2466. IF 17,879
  15. Pika T, Lochman P, Sandecka V, Maisnar V, Minarik J, Tichy M, Zapletalova J, Solcova L, Scudla V, Hajek R. Immunoparesis in MGUS - Relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. Neoplasma. 2015;62(5):827-32. doi: 10.4149/neo_2015_100. IF 1,642
  16. Pika T, Folprechtová P, Roubalová R, Lochman P, Ščudla V. Úspěšná léčba anti‑MAG neuropatie asociované s monoklonální gamapatií nejistého významu kombinací rituximabu s dexametazonem – kazuistika. Cesk Slov Neurol N. 2015, 78(4): 474-476 IF 0,159
  17. Sedlarikova L, Kubiczkova L, Kryukov F, Pelcova J, Adam Z, Pour L, Hajek R, Sevcikova S. Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(4):554-61.  doi: 10.5507/bp.2014.035. IF 1,661
  18. Sedlaříková L, Bešše L, Novosadová S, Kubaczková V, Radová L, Staník M, Krejčí M, Hájek R, Ševčíková S. MicroRNAs in urine are not biomarkers of multiple myeloma. J Negat Results Biomed. 2015;14(1):16. doi: 10.1186/s12952-015-0035-7. IF 1,47
  19. Sevcikova S, Paszekova H, Besse L, Sedlarikova L, Kubaczkova V, Almasi M, Pour L, Hajek R. Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):288-93. doi: 10.5507/bp.2015.014. IF 1,661
  20. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52. doi: 10.1056/NEJMoa1411321. IF 54,42
  21. Ščudla V, Pika T, Minařík J. The role of the assessment of heavy/light chain pairs of immunoglobulin in monoclonal gammopathies. Vnitr Lek. 2015;61(1):60-71.
  22. Ščudla V, Petrová P, Pika T, Lochman P, Minařík J, Bačovský J, Srovnalík K. Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma. Cas Lek Cesk. 2015;154(4):181-8.
  23. Ščudla V, Lochman P, Pika T, Zapletalová J, Minařík J, Bačovský J: Vyšetření párů těžkých/lehkých řetězců imunoglobulinu (Hevylite TM)- přínos pro stratifikaci mnohočetného myelomu? Klin Onkol 2015; 28(5): 359-369.
  24. Ščudla V, Lochman P, Pika T, Zapletalová J, Minařík J, Bačovský J. Analýza vztahu sérových hladin těžkých/lehkých řetězců imunoglobulinu (HevyliteTM) k výsledkům standardní gelové elektroforézy a nefelometrického vyšetření bílkovin séra při diagnóze mnohočetného myelomu. Cas Lek Cesk. 2015;28(5):359-69.
  25. Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J. Relationship of differences in immunoglobulin heavy/light chain pairs (HevyliteTM), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032.IF 1,661
  26. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A; European Myeloma Network. European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica. 2015;100(10):1254-66. doi: 10.3324/haematol.2014.117176. IF 5,868
  27. Všianská P, Říhová L, Varmužová T, Suská R, Kryukov F, Mikulášová A, Kupská R, Penka M, Pour L, Adam Z, Hájek R. Analysis of B-Cell Subpopulations in Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2015;15(4)e61-71 doi: 10.1016/j.clml.2014.12.003. IF 1,929

Other projects

  1. Adam Z, Szturz P, Koukalová R, Řehák Z, Pour L, Krejčí M, Šmardová L, Eid M, Volfová P, Čermáková Z, Křen L, Sokol F, Hanke I, Michalková E, Král Z, Mayer J. PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review. Vnitr Lek. 2015;61(3):251-9. 
  2. Adam Z, Kissová J, Pour L, Krejčí M, Ševčíková E, Koukalová R, Čermáková Z, Černá M, Král Z, Mayer J. Myopatie při Waldenströmově makroglobulinemii. Popis případu a přehled autoimunitních projevů monoklonálních imunoglobulinů typu IgM. Vnitř Lék 2015; 61(9): 821-828.
  3. Adam Z, Litzman J, Szturz P, Krejčí M, Vašků V, Pour L, Michalková E, Ševčíková S, Čermáková Z, Veselý K, Vaníček J, Pourová E, Král Z. Scleroedema adultorum Buschke a scleromyxedema. Česká dermatovenerologie 2015; 5(3):150-158.
  4. Fiserova B, Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. The miR-29 family in hematological malignancies. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(2):184-91. doi: 10.5507/bp.2014.037. IF 1,661
  5. Kubaczková V, Sedlaříková L, Bešše L, Almaši M, Hájek R, Ševčíková S. Potential of Cellfree Circulating DNA in Diagnosis of Cancer. Klin Onkol. 2015;28(4):251-9.
  6. Kubiczkova Besse L, Sedlarikova L, Kryukov F, Nekvindova J, Radova L, Almasi M, Pelcova J, Minarik J, Pika T, Pikalova Z, Scudla V, Krejci M, Adam Z, Pour L, Hajek R, Sevcikova S. Combination of serum microRNA-320a and microRNA-320b as a marker for Waldenström macroglobulinemia. Am J Hematol. 2015;90(3):E51-2. doi: 10.1002/ajh.23910. IF 3,477
  7. Palecek T, Fikrle M, Nemecek E, Bauerova L, Kuchynka P, Louch WE, Spicka I, Rysava R. Contemporary treatment of amyloid heart disease. Curr Pharm Des. 2015;21(4):491-506. Review. IF 3,288
  8. Pika T, Lochman P, Latalova P, Minařik J, Puščiznova P, Bačovsky J, Ščudla V. Problematika stanoveni monoklonalniho imunoglobulinu u nemocnych s AL amyloidozou. Klin. Biochem. Metab., 23 (44), 2015, No. 2, p. 37–41.
  9. Pika T, Lochman P, Kušnierova P, Heřmanova Z, Zapletalova J, Puščiznova P,Minařik J, Ščudla V. Stanoveni parů těžkych/lehkych řetězců imunoglobulinu u nemocnych s nově diagnostikovanou Waldenströmovou makroglobulinemii. Klin. Biochem. Metab., 23 (44), 2015, No. 2, p. 42–47.

 

2014

MM and MGUS

  1. Adam Z, Krejčí M, Pour L, Sevčíková E, Křivanová A, Rehák Z, Koukalová R, Cermáková Z, Vaníček J, Sevčíková S. Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014. Vnitr Lek. 2014 Oct;60(10):861-79.
  2. Dimopoulos MA, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Factors that influence health-related quality of life in newly diagnosed multiple myeloma patients aged ≥ 65 years treated with melphalan, prednisone, and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. Leuk Lymphoma. 2014;55(7):1489-97. doi: 10.3109/10428194.2013.847933. IF 2,605
  3. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A; European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358. IF 5,868
  4. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, Dimopoulos MA. The Role of Hdac Inhibitors in Patients with Relapsed/Refractory Multiple Myeloma. Leuk Lymphoma. 2014 Jan;55(1):11-8. doi: 10.3109/10428194.2013.797084. IF 2,605
  5. Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. IF 9,379
  6. Ludwig H, Miguel JS, Dimopoulos MA, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczyszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care.  Leukemia. 2014 May;28(5):981-92. doi: 10.1038/leu.2013.293. IF 9,379
  7. Ludwig H, Sonneveld P, Davies F, Bladé J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, Dimopoulos M, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. Oncologist. 2014;19(8):829-44. doi: 10.1634/theoncologist.2014-0042. IF 4,54
  8. Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, Greil R, Seebacher A, Pour L, Weißmann A, Adam Z. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014 Feb 13;123(7):985-91. doi: 10.1182/blood-2013-08-521468. IF 9,775
  9. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica.  2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500 IF 5,868
  10. Kubiczkova L, Pour L, Sedlarikova L, Hajek R, Sevcikova S. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014 Jun;18(6):947-61. doi: 10.1111/jcmm.12279. IF 3,698
  11. Machálková K., Maisnar V.:Rizikové faktory symptomatického mnohočetného myelomu. Klin. Biochem. Metab., 22 (43), 2014, 2, s. 70-73. ISSN 1210-7921.
  12. Maisnar V.:Efekt dlouhodobého podávání lenalidomidu. Acta medicinae, 2, Special 2014, s. 10-11. ISSN 1805-398X.
  13. Minařík J, Tichý T, Pika T, Bačovský J, Adamová D, Srovnalík K, Krejčí K, Zadražil J, Sčudla V. Bortezomib-based therapy in patients with light chain deposition disease. Vnitr Lek. 2014 Oct;60(10):821-6.
  14. Minařík J, Bačovský J, Pika T, Ščudla V Léčba pomalidomidem u relabujícího mnohočetného myelomu – první zkušenosti. Acta medica. [Epub ahead of print]
  15. Minarik J, Hrbek J, Pika T, Novak M, Bacovsky J, Herman M, Hrabalek L, Frysakova L, Pusciznova P, Scudla V. X-Ray in Multiple Myeloma – Not a „Golden Standard“ any More: Case Series. J Bone Mar Res. [Epub ahead of print]
  16. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. IF 24,725
  17. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. IF 17,879
  18. Paszekova H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S. High-Risk Multiple Myeloma: Different Definitions, Different Outcomes? Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):24-30. doi: 10.1016/j.clml.2013.09.004. IF 1,929
  19. Pavlistova L, Zemanova Z, Sarova I, Lhotska H, Berkova A, Spicka I, Michalova K. Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance. Cancer Genet. 2014;207(7-8):326-31. pii: S2210-7762(14)00141-0. doi: 10.1016/j.cancergen.2014.06.027. IF 2,417
  20. Pika T, Flodr P, Novák M, Lochman P, Látalová P, Minařík J, Ščudla V. Klinická problematika IgM monoklonálních gamapatií. Klin. Biochem. Metab. 2014;22(43),61-64
  21. Pika T, Kosatíková Z, Juráňová J, Mlčák P. Nekorpuskulární hyperviskózní syndromy v klinické praxi. Interní medicína pro praxi. 2014;16(2):52-54
  22. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409 IF 5,868
  23. Raja KR, Plasil M, Rihova L, Pelcova J, Adam Z, Hajek R. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom. 2014;86(4):220-8. doi: 10.1002/cyto.b.21109. IF 2,231
  24. Sedlaříková L, Sadílková K, Kubiczková L, Hájek R, Sevčíková S. Cytokine profiles of multiple myeloma and Waldenström macroglobulinemia. Klin Onkol. 2014;27(1):18-23.
  25. Staňková M, Bešše L, Sedlaříková L, Vrábel D, Hájek R, Sevčíková S. Cereblon -  a new target of therapy in the treatment of multiple myeloma. Klin Onkol. 2014;27(5):326-30
  26. Spicka I. Advances in multiple myeloma therapy during two past decades. Comput Struct Biotechnol J. 2014 Jun 11;10(16):38-40. doi: 10.1016/j.csbj.2014.05.005.
  27. Smetana J, Dementyeva E, Kryukov F, Nemec P, Greslikova H, Kupska R, Mikulasova A, Ihnatova I, Hajek R, Kuglik P. Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH. Neoplasma. 2013 Sep 20. doi: 10.4149/neo_2014_008 Neoplasma. 2014;61(1):48-55. IF 1,642
  28. Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P. Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience. Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. IF 2,706
  29. Svachova H, Kryukov F, Kryukova E, Sevcikova S, Nemec P, Greslikova H, Rihova L, Kubiczkova L, Hajek R. Nestin expression throughout multistep pathogenesis of multiple myeloma. Br J Haematol. 2014 Mar;164(5):701-9. doi: 10.1111/bjh.12689. IF 4,959
  30. van de Donk NW, Palumbo A, Johnsen HE, Engelhardt M, Gay F, Gregersen H, Hajek R, Kleber M, Ludwig H, Morgan G, Musto P, Plesner T, Sezer O, Terpos E, Waage A, Zweegman S, Einsele H, Sonneveld P, Lokhorst HM. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica. 2014;99(6):984-96. doi: 10.3324/haematol.2013.100552 IF 5,868 

Other projects

  1. Adam Z, Krejčí M, Pour L, Ševčíková E. Therapy of Waldenström´s macroglobulinaemia in the year 2014. Vnitr Lek. 2014 Feb;60(2):139-57.
  2. Adam Z, Řehák Z, Koukalová R, Bortlíček Z, Krejčí M, Pour L, Szturz P, Prášek J, Nebeský T, Adamová Z, Král Z, Mayer J. PET-CT documented complete remission of Erdheim-Chester disease, lasting more than 4 years from treatment initiation with cladribine. Vnitr Lek. 2014 May-Jun;60(5-6):499, 501-11.
  3. Sevčíková S, Kubiczková L, Sedlaříková L, Ríhová L, Kryukov F, Szturz P, Hajek R, Pour L, Adam Z. Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient. Klin Onkol. 2014;27(4):276-82.
  4. Szturz P, Sedivá A, Zurek M, Adam Z, Stork J, Cermáková Z, Steyerová P, Vokáčová A, Hrbek J, Sýkora M, Spička I, Mechl Z, Mayer J. Anakinra treatment in Schnitzler syndrome -results of the first retrospective multicenter study in six patients from the Czech Republic. Klin Onkol. 2014;27(2):111-26
  5. Szturz P, Adam Z, Rehák Z, Koukalová R. Xanthelasma palpebrarum responding to interleukin-1 blockade. Intern Med J. 2014 Jun;44(6):617-8. doi:10.1111/imj.12441. IF 1,699
  6. Sčudla V., Pika T., Látalová P., Flodr P., Maisnar V., Hájek R.: Česká myelomová skupina: Diagnostika a stratifikace systémové AL amyloidózy ve světle Doporučení České myelomové skupiny 2013. Klin. Biochem. Metab., 22 (43), 2014, 2, s. 49-60. ISSN 1210-7921.

2013

MM and MGUS

  1. Avet-Loiseau H, Durie BG, Cavo M, Attal M, Gutierrez N, Haessler J, Goldschmidt H, Hajek R, Lee JH, Sezer O, Barlogie B, Crowley J, Fonseca R, Testoni N, Ross F, Rajkumar SV, Sonneveld P, Lahuerta J, Moreau P, Morgan G; International Myeloma Working Group. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2013 Mar;27(3):711-7. doi: 10.1038/leu.2012.282. IF 10,164
  2. Čermáková Z, Gottwaldová J, Dastych M, Adam Z, Zahradová L. Efficient use of basic biochemical methods to prove the presence of monoclonal protein in the clinical diagnosis of malignant monoclonal gammopathy. Clin Chem Lab Med. 2013 Oct 1;51(10):e243-5. doi: 10.1515/cclm-2013-0090. IF 3,009
  3. Dementyeva E, Kryukov F, Kubiczkova L, Nemec P, Sevcikova S, Ihnatova I, Jarkovsky J, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med. 2013 Mar 23;11:77. doi: 10.1186/1479-5876-11-77. IF 3,459
  4. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-40. doi: 10.1016/S1470-2045(13)70398-X. IF 25,117
  5. Dimopoulos MA, Delforge M, Hájek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013 May;98(5):784-8. doi: 10.3324/haematol.2012.074534. IF 5,935
  6. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. IF 10,164
  7. Grzasko N, Hus M, Pluta A, Jurczyszyn A, Walter-Croneck A, Morawska M, Chocholska S, Hajek R, Dmoszynska A. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. Hematol Oncol. 2013 Mar;31(1):41-8. doi: 10.1002/hon.2018. IF 2,036
  8. Hájek R, Plonková H, Gumulec J. Thalidomide in the treatment of multiple myeloma: focus on combination with bortezomib. Klin Onkol. 2013;26(3):163-9.
  9. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013 Dec;163(5):551-64. doi: 10.1111/bjh.12563. IF 4,942
  10. Kryukov F, Dementyeva E, Kubiczkova L, Jarkovsky J, Brozova L, Petrik J, Nemec P, Sevcikova S, Minarik J, Stefanikova Z, Kuglik P, Hajek R. Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia. Genomics. 2013 Oct;102(4):243-9. doi: 10.1016/j.ygeno.2013.06.007. IF 3,010
  11. Kryukov F, Nemec P, Dementyeva E, Kubiczkova L, Ihnatova I, Budinska E, Jarkovsky J, Sevcikova S, Kuglik P, Hajek R. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leuk Lymphoma. 2013 Sep;54(9):1982-8. doi: 10.3109/10428194.2013.764416. IF 2,301
  12. Kubiczková L, Dúcka M, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S. Cyclins d in regulation and dysregulation of the cell cycle in multiple myeloma. Klin Onkol. 2013;26(5):313-8.
  13. Kubiczková L, Matějíková J, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S. Proteasome inhibitors in treatment of multiple myeloma. Klin Onkol. 2013;26(1):11-8. Review.
  14. Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. IF 18,038
  15. Mathu Raja KR, Hajek R. Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. Oncoimmunology. 2013 Sep 1;2(9):e25619.
  16. Matějíková J, Kubiczková L, Sedlaříková L, Potáčová A, Hájek R, Sevčíková S. Degradation of proteins by ubiquitin proteasome pathway. Klin Onkol. 2013;26(4):251-6.
  17. Minarik J, Sandecka V, Maisnar V, Gregora E, Spicka I, Starostka D, Plonkova H, Jarkovsky J, Walterova L, Wrobel M, Adamova D, Pika T, Melicharova H, Pour L, Radocha J, Pavlicek P, Straub J, Gumulec J, Bacovsky J, Adam Z, Scudla V, Hajek R. 10 years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group. Leuk Res. 2013 Sep;37(9):1063-9. doi: 10.1016/j.leukres.2013.06.019. IF 2,764
  18. Orság J, Pika T, Kosatíková Z, Lochman P, Žamboch K, Minařík J, Hrubý M, Ščudla V, Zadražil J. Hemodialýza s použitím „high cut-off“ membrán při selhání ledvin u mnohočetného myelomu – první zkušenosti. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 88–92.
  19. Pika T, Lochman P, Maisnar V, Tichý M, Minařík J, Hájek R, Ščudla V. Klinicko-laboratorní aspekty biklonální gamapatie nejistého významu – BGUS. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 83–87
  20. Pika T, Lochman P, Flodr P, Mičková P, Novák M, Jehlíková Z, Hamplová A, Minařík J, Bačovský J, Kučerová L, Jarošová M, Ščudla V. Klinické aspekty „pravé“ nesekretorické formy mnohočetného myelomu. Transfuze Hematol. dnes, 19, 2013, No. 1, p. 27-32.
  21. Radocha J, Maisnar V, Zavrelová A, Cermanová M, Lánská M, Kmonícek M, Jebavý L, Bláha M, Malý J, Zák P. Fifteen years of single center experience with stem cell transplantation for multiple myeloma: a retrospective analysis. Acta Medica (Hradec Kralove). 2013;56(1):9-13.
  22. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul;37(7):829-37. doi: 10.1016/j.leukres.2013.03.006. IF 2,764
  23. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 1;31(4):448-55. doi: 10.1200/JCO.2012.41.6180. IF 18,038
  24. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R. Serum miR-29a as a marker of multiple myeloma. Leuk Lymphoma. 2013;54(1):189-91. IF 2,301
  25. Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. IF 1,667
  26. Špička I, Klánová M. Multiple myeloma. Vnitr Lek. 2013 Jul;59(7):627-30.
  27. Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment. Leuk Lymphoma. 2013 Jun;54(6):1324-6. doi: 10.3109/10428194.2012.738816. IF 2,301
  28. Uherková L, Vančurová I, Vyhlídalová I, Pleschnerová M, Spička I, Mihalová R, Březinová J, Hodný Z, Cermáková K, Polanská V, Marinov I, Jedelský PL, Kuželová K, Stöckbauer P. Novel human multiple myeloma cell line UHKT-893. Leuk Res. 2013 Mar;37(3):320-6. doi: 10.1016/j.leukres.2012.12.004. IF 2,764

Amyloidosis

  1. Adam Z, Krejčí J, Krejčí M, Němec P, Spinarová L, Zampachová V, Cermáková Z, Pika T, Pour L, Kořístek Z, Tomíška M, Szturz P, Král Z, Mayer J. Heart transplantation and the subsequent treatment of AL amyloidosis. Vnitr Lek. 2013 Feb;59(2):136-47.
  2. Adam Z, Sčudla V, Krejčí M, Cermáková Z, Pour L, Král Z. Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials. Vnitr Lek. 2013 Jan;59(1):37-58. Review.
  3. Fikrle, M., Paleček, T., Kuchynka, P., Němeček, E., Bauerová, L., Straub, J., Ryšavá, R. Cardiac amyloidosis: A comprehensive review. Cor et Vasa. 2013, 55(1), e60-e75. ISSN 0010-8650.
  4. Pika T, Lochman P, Vymětal J, Metelka R, Minařík J, Látalová P, Zapletalová J, Bačovský J, Sčudla V. Attainment of Complete Hematological Remission is Crucial for Extended Survival of AL Amyloidosis Patients with Cardiac Involvement. Klin Onkol. 2013;26(5):343-7.
  5. Pika T, Lochman P, Vymětal J, Metelka R, Flodr P, Minařík J, Látalová P, Zapletalová J, Bačovský J, Sčudla V. The importance of cardiac bio-marker assay for the stratification and monitoring of AL amyloidosis patients - single center experience. Vnitr Lek. 2013 Fall;59(9):776-81.
  6. Pika T, Lochman P, Flodr P, Minařík J, Látalová P, Bačovský J, Ščudla V. Význam stanovení vybraných laboratorních parametrů v diagnostice, stratifikaci a sledování nemocných s AL amyloidózou. Klin. Biochem. Metab., 21 (42), 2013, No. 2, p. 79–82.
  7. Szturz P, Kyclová J, Moulis M, Navrátil M, Adam Z, Vaníček J, Mayer J. Extensive Al amyloidosis presenting with recurrent liver hemorrhage and hemoperitoneum: case report and literature review. Klin Onkol. 2013;26(1):49-52. Review. 

Other projects

  1. Adam Z, Szturz P, Vaníček J, Moulis M, Pour L, Krejčí M, Hájek R, Mayer J. Cladribine (2-chlorodeoxyadenosine) in frontline chemotherapy for adult Langerhans cell histiocytosis: A single-center study of seven cases. Acta Oncol. 2013 Jun;52(5):994-1001. doi: 10.3109/0284186X.2012.716164. IF 2,867
  2. Adam Z, Szturz P, Křen L, Krejčí M, Pour L, Svoboda T, Hanke I, Penka I, Koukalová R, Rehák Z, Cervinková I, Storková T, Král Z, Mayer J. PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview. Vnitr Lek. 2013 Apr;59(4):301-12.
  3. Adam Z, Pejchalová A, Chlupová G, Ríhová L, Pour L, Krejčí M, Cervinek L, Král Z, Mayer J. Cold agglutinin disease - no response to glucocorticoids and rituximab, what treatment is best for the 3rd line of therapy? Case report and review of the literature. Vnitr Lek. 2013 Fall;59(9):828-40.
  4. Szturz P, Hlavatý L, Prášek J, Dvořáková D. Erdheim-Chester disease and Schnitzler syndrome: so near, and yet so far. Int J Hematol. 2013 Oct;98(4):379-81. doi: 10.1007/s12185-013-1437-2. IF 1,681
  5. Szturz P, Adam Z, Rehák Z, Koukalová R, Sprláková-Puková A, Michalka J, Smardová L, Volfová P, Lengerová M, Mayer J. Castleman disease: retrospective single-center study of therapeutic results in 10 patients. Klin Onkol. 2013;26(2):124-34.

2012

  1. Adam Z, Elleder M, Moulis M, Tichý M, Cervinková I, Rehák Z, Koukalová R, Fojtík Z, Hanke I, Pour L, Krejčí M, Zahradová L, Szturz P, Hájek R, Král Z, Mayer J. The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis. Vnitr Lek. 2012 Mar;58(3):241-52.
  2. Al-Sahmani M, Trnavská I, Antošová M, Antošová L, Kissová J, Kaisarová B, Adam Z, Buliková A, Penka M, Hájek R. Prognostic significance of morphology in multiple myeloma. Klin Onkol. 2012;25(2):103-9.
  3. Buresova I, Cumova J, Kovarova L, Stossova J, Dementyeva E, Kryukov F, Sevcikova S, Svachova H, Hajek R. Bone marrow plasma cell separation - validation of separation algorithm. Clin Chem Lab Med. 2012;50(6):1139-40. IF 2,150
  4. Cumová J, Jedličková L, Potěšil D, Sedo O, Stejskal K, Potáčová A, Zdráhal Z, Hájek R. Comparative plasma proteomic analysis of patients with multiple myeloma treated with bortezomib-based regimens. Klin Onkol. 2012;25(1):17-25.
  5. Fišerová B, Kubiczková L, Sevčíková S, Hájek R. [Implication of bone marrow microenvironment in pathogenesis of multiple myeloma]. Klin Onkol. 2012;25(4):234-40. Review.
  6. Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012;30(20):2475-82. IF 18,372
  7. Grzasko N, Hus M, Chocholska S, Pluta A, Hajek R, Dmoszynska A. 1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. Leuk Lymphoma. 2012;53(12):2500-3. PubMed PMID: 22497640. IF 2,580
  8. Hájek R, Bryce R, Ro S, Klencke B, Ludwig H. Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012;12:415. doi: 10.1186/1471-2407-12-415. IF 3,011
  9. Ross F, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O' Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michaux L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE. Report from the european myeloma network on interphase FISHin multiple myeloma and related disorders. Haematologica. 2012;97(8):1272-7 IF 6,424
  10. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; on behalf of the International Myeloma Working Group; International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157. doi: 10.1038/leu.2011.196. IF 9,561
  11. Morgan G, Johnsen HE, Goldschmidt H, Palumbo A, Cavo M, Sonneveld P, Miguel JS, Chim C, Browne P, Einsele H, Waage A, Turesson I, Spencer A, Hajek R, Ludwig H, Hemminki K, Houlston R. MAGIC (MyelomA Genetics International Consortium). Leuk Lymphoma. 2012;53(5):796-800 IF 2,580
  12. Kropff M, Giongco-Baylon H, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Blade J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97(5):784-91 IF 6,424
  13. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master.J Transl Med. 2012 Sep 3;10:183. doi: 10.1186/1479-5876-10-183. IF 3,474
  14. Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J. Induction treatment of light chain deposition disease with bortezomib - rapid hematological response with persistence of renal involvement. Leuk Lymphoma. 2012;(2):330-1 IF 2,580
  15. Minarik J, Pika T, Bacovsky J, Petrova P, Langova K, Scudla V. Prognostic value of hepatocyte growth factor, syndecan-1, and osteopontin in multiple myeloma and monoclonal gammopathy of undetermined significance. ScientificWorldJournal. 2012;2012:356128
  16. Minarik J, Pika T, Bacovsky J, Langova K, Scudla V. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol. 2012;159(1):111-3. doi: 10.1111/j.1365-2141.2012.09233.x. IF 4,941
  17. Minařík J., Pika T., Bačovský J., Ščudla V.Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem – kazuistika. Interní Med. 2012; 14(12): 478-480
  18. Minařík J., Ščudla V. Vliv prognostických ukazatelů na výsledky léčby lenalidomidem u nemocných s mnohočetným myelomem. Farmakoterapie;2012 (8) 5: 552-555
  19. Muthu Raja KR, Rihova L, Zahradova L, Klincova M, Penka M, Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012;7(10):e47077. doi: 10.1371/journal.pone. 0047077. IF 4,092
  20. Muthu Raja KR, Kovarova L, Hajek R. Induction by Lenalidomide and Dexamethasone Combination Increases Regulatory Cells of Previously Untreated Multiple Myeloma Patients. Leuk Lymphoma. 2012;(7):1406-8  IF 2,580
  21. Muthu Raja KR, Kubiczkova L, Rihova L, Piskacek M, Vsianska P, Hezova R, Pour L, Hajek R. Functionally Suppressive CD8 T Regulatory Cells Are Increased in Patients with Multiple Myeloma: A Cause for Immune Impairment. PLoS One. 2012;7(11):e49446. IF 4,092
  22. Nemec P, Zemanova Z, Kuglik P, Michalova K, Tajtlova J, Kaisarova P, Oltova A, Filkova H, Holzerova M, Balcarkova J, Jarosova M, Rabasova J, Hruba M, Spicka I, Gregora E, Adam Z, Scudla V, Maisnar V, Schutzova M, Hajek R. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leuk Lymphoma. 2012;53(5):920-7 IF 2,580
  23. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger  H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69. IF 53,298
  24. Pika, T., Lochman, P., Klincová, M., Maisnar, V., Tichý, M., Zapletalová, J., Sandecká, V., Ščudla, V., Hájek, R.: Suprese alternativního páru imunoglobulinu koreluje s mírou rizikovosti MGUS výrazněji nežli suprese hladin polyklonálních imunoglobulinů – dílčí výsledky vyšetření HevyLiteTM u MGUS. Klin Biochem Metab 20(41),2012,2:63-71.
  25. Pika, T., Lochman, P., Minařík, J., Bačovský, J., Ščudla, V.: Úskalí interpretace výsledků společné analýzy hladin volných lehkých řetězců a elektroforézy séra. Klin Biochem Metab 20(41),2012,2:59-62.
  26. Sčudla V, Minařík J, Pika T. Light chain deposition disease. Vnitr Lek. 2012;58(1):38-43.
  27. Ščudla,V., Tichý,T., Minařík, J., Pika,T., Krejčí, K., Zadražil, J.: Onemocnění z depozice lehkých řetězců imunoglobulinu (light chain deposition disease). Klin Biochem Metab 2012; 20(4): 52-58.
  28. Ščudla,V.,Adam, Z.: Současné možnosti diagnostiky a léčby myelomové kostní nemoci v klinické praxi. Vnitř Lék 2012;58:164-174.
  29. Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R.Mechanism of immunomodulatory drugs in multiple myeloma. Leuk Res. 2012;36(10):1218-24. doi: 10.1016/j.leukres.2012.05.010. IF 2,923
  30. Vanicek J, Szturz P, Rehak Z, Kianicka B, Bulik M. Benefits of individual imaging methods for diagnosis and monitoring of activity of multiple myeloma. Klin Onkol. 2012;25(3):166-72.
  31. Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, Pour L, Krivanova A, Sandecka V, Hajek R. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results. Neoplasma. 2012;59(4):440-9. IF 1,440

Other projects

  1. Adam Z, Szturz P, Bučková P, Cervinková I, Koukalová R, Rehák Z, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J. Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature. Vnitr Lek. 2012;58(4):313-8.
  2. Adam Z, Pour L, Matýšková M, Krejčí M, Tomíška M, Szturz P, Rehák Z, Koukalová R, Křikavová L, Nebeský T, Neuman C, Navrátil M, Hájek R, Král Z, Mayer J. Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide. Vnitr Lek. 2012;58(2):145-53.
  3. Adam Z, Rehák Z, Koukalová R, Szturz P, Krejčí M, Pour L, Zahradová L, Moulis M, Kodet R, Nebeský T, Brejcha M, Adamová Z, Hájek R, Mayer J. Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation. Vnitr Lek. 2012;58(1):62-71.
  4. Adam Z, Matýšková M, Tomíška M, Rehák Z, Koukalová R, Křikavová L, Pour L, Krejčí M, Szturz P, Zahradová L, Mechl M, Moulis M, Vaníček J, Neuman C, Navrátil M, Veselý K, Hájek R, Mayer J. Six-year follow-up of a patient with multiple angiomatosis involving skeleton, thoracic and abdominal cavities and the gut wall. Klin Onkol. 2012;25(1):47-62.
  5. Adam Z, Veselý K, Motyčková I, Szturz P, Koukalová R, Rehák Z, Stouracová A, Vaníček J, Krejčí M, Pour L, Zahradová L, Hájek R, Král Z, Mayer J. Eyelids with yellow granulomas and cough - periocular xanthogranuloma associated with adult-onset asthma. A case study and an overview of clinical forms of juvenile xanthogranuloma and its therapy. Vnitr Lek. 2012;58(5):365-77.
  6. Adam Z, Szturz P, Duraš J, Pour L, Krejčí M, Rehák Z, Koukalová R, Navrátil M, Hájek R, Král Z, Mayer J. [Treatment of Langerhans cells histiocytosis by cladribin reached long-term complete remission in 9 out of 10 adult patients]. Klin Onkol. 2012;25(4):255-61.
  7. Adam Z, Chlupová G, Neumann A, Jakubcová B, Simonides J, Adamová Z, König J, Krupa P, Szturz P, Pour L, Krejčí M, Hájek R, Král Z, Mayer J.[Teleangiectasia hereditaria haemorrhagica--Osler-Weber-Rendu syndrome. Case study and treatment experience]. Vnitr Lek. 2012 Jun;58(6):477-89.
  8. Adam Z, Elleder M, Moulis M, Tichý M, Cervinková I, Rehák Z, Koukalová R, Fojtík Z, Hanke I, Pour L, Krejčí M, Zahradová L, Szturz P, Hájek R, Král Z, Mayer J. [The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis]. Vnitr Lek. 2012 Mar;58(3):241-52.
  9. Adam Z, Szturz P, Pour L, Krejčí M, Zahradová L, Tomíška M, Král Z, Koukalová R, Rehák Z, Mayer J. [Cladribine is highly effective in the treatment of Langerhans cell histiocytosis and rare histiocytic disorders of the juvenile xanthogranuloma group]. Vnitr Lek. 2012 Jun;58(6):455-65. Review.
  10. Adam Z,  Szturz P, Krejčí M, Pour L, Zahradová L, Řehák Z, Koukalová R,  Král Z, Vašků V, Mayer J: Kožní a mimokožní projevy histiocytózy z Langerhansových buněk v obrazech. Česká dermatovenerologie 2012; 2 (č. 1): 22-27
  11. Adam Z, Pour L, Krejčí M, Zahradová L, Szturz P, Koukalová R, Rehák Z, Nebeský T, Hájek R, Král Z, Mayer J. [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].Vnitr Lek. 2012 Nov;58(11):856-66.
  12. Adam Z, Štork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Čermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer M: Výsledky léčby AL-amyloidózy léčebnými režimy obsahujícími bortezomib, dexametazon a dále cyklofosfamid anebo doxorubicin. Vnitřní lék 2012; 58(12):896-903
  13. Minarik J, Scudla V, Bacovsky J, Pika T, Ctvrtlik F, Metelkova I, Myslivecek M. Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012 Mar;156(1):52-7.
  14. Szturz P, Rehák Z, Koukalová R, Adam Z, Krejčí M, Pour L, Zahradová L, Vaníček J, Nebeský T, Hájek R, Mayer J. Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. Nucl Med Biol. 2012;39(3):429-36 IF 3,023
  15. Szturz P, Adam Z, Rehák Z, Koukalová R, Slaisová R, Stehlíková O, Chovancová J, Klabusay M, Krejčí M, Pour L, Hájek R, Mayer J. Lenalidomide proved effective in multisystem Langerhans cell histiocytosis. Acta Oncol. 2012;51(3):412-5 IF 3,330
  16. Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Feit J, Křen L, Dorbová D, Fojtík Z, Obrovská M, Krejčí M, Pour L, Hájek R, Mayer J. Cytokine analysis in a patient with relapsing Kikuchi-Fujimoto disease. Leuk Lymphoma. 2012;53(4):743-5 IF 2,580
  17. Szturz P, Adam Z, Chovancová J, Stehlíková O, Klabusay M, Rehák Z, Koukalová R, Krejčí M, Pour L, Zahradová L, Hájek R, Mayer J. Lenalidomide: a new treatment option for Castleman disease. Leuk Lymphoma. 2012;53(10):2089-91 IF 2,580
  18. Szturz P, Adam Z, Moulis M, Smardová L, Klincová M, Slaisová R, Koukalová R, Rehák Z, Volfová P, Chovancová J, Stehlíková O, Mayer J. [Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations - case report and literature review]. Vnitr Lek. 2012 Sep;58(9):679-90.